FRANKLIN, Tenn.--(BUSINESS WIRE)--Sept. 18, 2006--BioMimetic Therapeutics, Inc. (NASDAQ: BMTI) today announced that William V. Giannobile, DDS, DMSc provided 12 and 24 month follow-up results from the pivotal clinical trial for the Company's lead product, GEM 21S Growth-factor Enhance Matrix, for the treatment of periodontal disease and gingival recession. The data demonstrate continued long-term efficacy for GEM 21S treatment, with improved bone growth observed throughout the 24 month observation period compared to control treatment. The data were released today at the 92nd Annual Meeting of the American Academy of Periodontology (AAP) in San Diego, CA.
